Physician profile
Punitha Krishnasamy
NPI 1447731112
$7,246.63
in general payments reported to CMS, 2019-2025
14 companies · $4,392 in 2025
The $4,392 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,355 · 2024: $1,500 · 2025: $4,392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,637 · Consulting Fee: $1,388 · Travel and Lodging: $1,210 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,636.57 |
| Consulting Fee | $1,387.50 |
| Travel and Lodging | $1,210.41 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $3,223.25 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $715.95 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $686.88 | 2023-2025 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $609.47 | 2023-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $514.44 | 2023-2025 | Uzedy, Austedo, Austedo Xr |
| Neurocrine Biosciences, INC. | $428.57 | 2023-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $232.76 | 2024 | Auvelity |
| Vanda Pharmaceuticals INC. | $231.97 | 2024-2025 | Fanapt |
| Ironshore Pharmaceuticals INC. | $156.68 | 2023 | Jornay Pm |
| Abbvie INC. | $124.69 | 2025 | |
| Dexcom, INC. | $116.71 | 2023 | Dexcom G7 Gss (161) |
| Novo Nordisk INC | $102.66 | 2023 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $54.00 | 2024-2025 | Invega Sustenna |
| Lundbeck LLC | $48.60 | 2025 | Abilify Asimtufii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Punitha Krishnasamy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.